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Abstract
Objective
To investigate the long-term safety and eﬃcacy of weekly subcutaneous IgPro20 (Hizentra,
CSL Behring) in chronic inﬂammatory demyelinating polyneuropathy (CIDP).
Methods
In a 48-week open-label prospective extension study to the PATH study, patients were initially
started on 0.2 g/kg or on 0.4 g/kg weekly and—if clinically stable—switched to 0.2 g/kg weekly
after 24 weeks. Upon CIDP relapse on the 0.2 g/kg dose, 0.4 g/kg was (re)initiated. CIDP
relapse was deﬁned as a deterioration by at least 1 point in the total adjusted Inﬂammatory
Neuropathy Cause and Treatment score.
Results
Eighty-two patients were enrolled. Sixty-two patients initially received 0.4 g/kg, 20 patients 0.2
g/kg weekly. Seventy-two received both doses during the study. Sixty-six patients (81%)
completed the 48-week study duration. Overall relapse rates were 10% in 0.4 g/kg–treated
patients and 48% in 0.2 g/kg–treated patients. After dose reduction from 0.4 to 0.2 g/kg, 51%
(27/53) of patients relapsed, of whom 92% (24 of 26) improved after reinitiation of the
0.4 g/kg dose. Two-thirds of patients (19/28) who completed the PATH study without relapse
remained relapse-free on the 0.2 g/kg dose after dose reduction in the extension study. Sixty-
two patients had adverse events (AEs) (76%), of which most were mild or moderate with no
related serious AEs.
Conclusions
Subcutaneous treatment with IgPro20 provided long-term beneﬁt at both 0.4 and 0.2 g/kg
weekly doses with lower relapse rates on the higher dose. Long-term dosing should be in-
dividualized to ﬁnd the most appropriate dose in a given patient.
Classification of evidence
This study provides Class IV evidence that for patients with CIDP, long-term treatment with
SCIG beyond 24 weeks is safe and eﬃcacious.
MORE ONLINE
Class of Evidence
Criteria for rating
therapeutic and diagnostic
studies
NPub.org/coe
From the Department of Neurology (I.N.S.), Amsterdam University Medical Centers, University of Amsterdam, The Netherlands; Spaarne Gasthuis (I.N.S.), Haarlem, The Nether-
lands; CSL Behring (O.M., M.P., B.L.D.), Marburg, Germany and King of Prussia, PA; Department of Medicine (Neurology) (V.B.), University Health Network, University of Toronto,
Canada; Medical Statistics (N.G.), Department of Biomedical Data Sciences, Leiden University Medical Center, The Netherlands; Department of Neurology (H.-P.H.), Medical Faculty,
Heinrich Heine University, Du¨sseldorf, Germany; Department of Neurology (R.A.L.), Cedars-Sinai Medical Center, Los Angeles, CA; Department of Neurology (G.S.), Nagoya University
Graduate School of Medicine, Japan; Department of Neurology (D.R.C.), Johns Hopkins University School of Medicine, Baltimore, MD; and Department of Neurology (I.S.J.M.),
Maastricht University Medical Center, The Netherlands.
Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.
The Article Processing Charge was funded by CSL Behring.
PATH study group coinvestigators are listed in Appendix 2.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading
and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. 1
Recently, subcutaneous immunoglobin (SCIG) IgPro20
(Hizentra, CSL Behring, Marburg, Germany/King of Prussia,
PA) was shown to be eﬃcacious and well tolerated as mainte-
nance treatment for chronic inﬂammatory demyelinating poly-
neuropathy (CIDP) in a randomized, placebo-controlled trial:
the PATH study.1 This study showed that 2 doses of IgPro20
were eﬃcacious in preventing disease relapse over 24 weeks with
a good safety proﬁle in patients whowere previously shown to be
dependent on intravenous immunoglobulin (IVIG) treat-
ment. Systemic side eﬀects were reduced using SCIG com-
pared with IVIG, which might be explained by diﬀerences in
pharmacokinetics.2–6 SCIG increases patient autonomy and
quality of life and may lead to cost savings (including cost for
premedication and complication management, as well as time
of various health care professionals) depending on local country-
speciﬁc rules and pricing.7–10 Increased patient satisfaction has
also been suggested in patients with CIDP treated with SCIG.11
However, the long-term eﬀect of weekly SCIG in CIDP beyond
24 weeks has not been studied adequately with appropriate dis-
ability outcome measures.12 We conducted a multicenter, open-
label extension study to the PATH study, designed to provide
long-term safety and eﬃcacy data of the 2 doses of IgPro20 (0.2
and 0.4 g/kg weekly) in patients with CIDP and to conﬁrm that
SCIG is an alternative long-term maintenance treatment option
for patients with CIDP who were previously treated with IVIG.
Methods
Design
This open-label prospective extension study was conducted
by the PATH study group. The primary study objective was to
determine the long-term safety of SCIG IgPro20 in patients
with CIDP, whereas the secondary study objective was to
determine the long-term eﬃcacy. The study was designed to
provide Class IV evidence that for patients with CIDP, long-
term treatment with SCIG beyond 24 weeks is safe and eﬃ-
cacious and provides an alternative to IVIG.
The study design in the original extension study protocol and
the study design after a protocol amendment diﬀered in the
requirements for patient entry from the PATH study and in
the SCIG dosing regimens (see below). The change in pro-
tocol arose from the interest to observe maintenance of
patients who were started on the 0.2 g/kg dose.
Standard protocol approvals, registrations,
and patient consents
All participants gave written informed consent before any
study-speciﬁc procedures were performed. The study
protocol was approved by the ethics committees of all par-
ticipating centers. The study was overseen by a steering
committee, which provided overall supervision and scientiﬁc
support for the study, and a safety review committee (SRC),
which periodically reviewed and evaluated safety data to
provide recommendations regarding the patient safety. The
SRC had the competence to continue as planned, to stop, to
temporarily suspend, or to amend the study. The PATH study
is registered with Clinicaltrials.gov, number NCT01545076.
Participants
Patients who had completed the PATH study or who had
successfully been rescued from a relapse during the PATH
study were eligible for participation in the extension study.
Patients eligible for the PATH study were aged at least 18
years and had been diagnosed with deﬁnite or probable CIDP
according to the European Federation of Neurological
Societies/Peripheral Nerve Society criteria13 and had
responded to IVIG. Inclusion criteria of the original extension
protocol: written informed consent was obtained; random-
ized and received SCIG or placebo in the PATH study; and
gap between studies was not longer than 8 weeks (exceptions
applied if the extension study was not yet open for enrollment
at the site). Inclusion criteria after protocol amendment: the
patient had completed the PATH study (SC week 25) or was
successfully rescued from a relapse during SCIG or placebo
treatment.
Exclusion criteria were similar to those used in the original
PATH study.14 The following additional exclusion criteria
were applied after the protocol amendment: gap between
studies of more than 1 day; new medical condition and/or
social behavior (i.e., alcohol, drug, or medication abuse)
during the PATH study that in the judgment of the in-
vestigator could increase risk to the patient, interfere with
outcome evaluation and/or the conduct of the study.
Enrollment into the extension study started in 2014, more
than 2 years after the start of the PATH study. As a conse-
quence, most patients had a time gap between completion of
PATH and entry into the extension study during which they
were treated with IVIG.
Treatment and follow-up
In the PATH study, patients were treated with SCIG (0.2 or
0.4 g/kg weekly) or with placebo. The PATH study was
blinded until after all extension study patients were enrolled.
In the original extension study protocol, 0.4 g/kg was used as
the initial weekly dose. Patients who did not relapse for 24
weeks were then switched to (open-label) 0.2 g/kg weekly
Glossary
AE = adverse event;CIDP = chronic inﬂammatory demyelinating polyneuropathy; INCAT = Inﬂammatory Neuropathy Cause
and Treatment; I-RODS = Inﬂammatory Neuropathy-Rasch-Built Overall Disability Scale;MRC = Medical Research Council;
SAE = serious AE; SRC = Safety Review Committee.
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(low dose) for another 24 weeks. After a protocol amend-
ment, the low dose was chosen as the initial dose. Patients
remained on low dose for 48 weeks unless relapse occurred.
Patients who relapsed on low-dose SCIG were given the
option to switch to high-dose SCIG. Patients who relapsed on
high-dose SCIG were given the option to remain on high dose
or be discontinued depending on the patient and inves-
tigator’s judgment. Patients who remained on high dose had
to successfully recover from relapse within 4 weeks (±2 days)
and remain on this dose until week 48 or were otherwise
discontinued from the study.
Patients were previously trained on the SC technique during
the PATH study. All patients enrolled in this study received
weekly SCIG. SCIG volume was administered in 1 infusion
session for the low dose, and in 2 approximately equal-volume
infusion sessions for the high dose, for 1 or 2 consecutive days.
The total volume infused could be subdivided over multiple
SC infusion sites. Moreover, 2 infusion pumps, if needed,
could be used in parallel. The maximum infusion rate was 35
mL/h, as tolerated. For patients enrolled under the original
extension study protocol, the maximum infusion volume was
40 mL/per site, but for patients enrolled after amendment 1,
the maximum volume was 50 mL/per site, as tolerated.
It was recommended to change the infusion site(s) with each
administration. Appropriate infusion sites were, e.g., the ab-
domen, thighs, and lateral hip. The number of infusion sites
depended on the total volume administered. If needed, ad-
ditional infusion sites were used consecutively. The goal was
to increase the patient’s comfort while decreasing pain and
infusion time. A patient who did not tolerate a speciﬁc volume
per infusion site could reduce the volume per site as needed.
Any change of volume or rate per infusion site was approved
by the investigator.
The following concomitant CIDP treatments were not per-
mitted during the study: other nonstudy IgGs, rituximab,
alemtuzumab, plasma exchange, interferon, tumor necrosis
factor alpha inhibitors, ﬁngolimod, cyclophosphamide, and
any other systemic immunosuppressive medications, except
those medications permitted during the PATH study. Con-
comitant CIDP treatments other than those listed above were
permitted, provided that their dose and frequency were kept
stable during the whole study: e.g., methotrexate, azathio-
prine, mycophenolate, or corticosteroids (maintenance dose
≤20 mg/d).
Treatment compliance wasmonitored. Patients were required
to ﬁll a “drug accountability form,” which was checked by the
local investigator and sponsor. Patients also had to return
empty and not fully used vials.
Definition of relapse, successful recovery, and
outcome measures
CIDP relapse was deﬁned as a deterioration (i.e., increase) by
at least 1 point in the total adjusted Inﬂammatory Neuropathy
Cause and Treatment (INCAT) score (range 0 [healthy] to
10 [unable to make any purposeful movements with arms or
legs])15 compared with baseline. Successful recovery after
a relapse was deﬁned as the return of the adjusted INCAT
score back to (or better than) the baseline score. Baseline
scores were deﬁned as the scores assessed at the enrollment
visit; for patients enrolled after protocol amendment, baseline
assessments were performed at the same time as the com-
pletion visit of the PATH study. Other eﬃcacy measures were
mean grip strength assessed for both hands separately using
the hand-held Martin Vigorimeter,16 Medical Research
Council (MRC) sum score (range 0–80; including shoulder
abduction, elbow ﬂexion, wrist extension, index ﬁnger ab-
duction, hip ﬂexion, knee extension, foot dorsiﬂexion, and
great toe dorsiﬂexion),17 and Inﬂammatory Neuropathy-
Rasch-Built Overall Disability Scale (I-RODS) (range 0 [most
severe activity and social participation limitations] to 100 [no
activity and social participation limitations]).18 INCAT
scores, grip strength, MRC sum score, and I-RODS were
assessed at baseline; week 2, 9, 25, 33, and at the completion
visit (week 49); at any unscheduled visit; and at a 4-week
follow-up visit after a relapse. To assess the safety and toler-
ability of SCIG, adverse events (AEs) per infusion and the
number and percentage of patients with AEs were de-
termined. We assessed the patient’s preference with a ques-
tionnaire.14 Furthermore, we measured serum IgG trough
concentrations (before administration of the study drug).
Safety analysis
As most patients received both doses during the study, AEs
were allocated to either the high or low dose, depending on
the dose when the AE started.
Statistical analysis
This study included patients from the preceding PATH study.
Descriptive statistics were used to analyze the results. The
Statistical Analysis System (SAS) software package (SAS In-
stitute, Cary, NY) version 9.2 or higher was used for statistical
analyses.
Data availability
CSL will only consider requests to share individual patient
data that are received from systematic review groups or bona-
ﬁde researchers (see table e-1, links.lww.com/NXI/A124 for
more information).
Results
A total of 82 patients of 172 PATH study patients were en-
rolled in the extension study between 2014 and 2016 from 33
sites. Baseline characteristics of these patients are shown in
table 1, and the patient’s disposition by treatment and relapse
status in the PATH trial is presented in table 2. Sixty-three
patients (77%) were enrolled under the original extension
study protocol (i.e., with 0.4 g/kg planned as the initial weekly
high dose), and 19 (23%) were enrolled after approval of
a protocol amendment (i.e., with weekly low dose [0.2 g/kg]
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planned as the initial dose) (ﬁgure). Two patients who were
planned to start with the high dose actually were started on
the low dose, and 1 patient planned to start with the low dose
was started on the high dose. Thus, 62 patients started on the
high dose and 20 on the low dose. Fifty-two patients who
started on the high dose were switched to the low dose after
24 weeks of treatment, which was a planned procedure
according to the protocol. In addition, patients who relapsed
on the low dose were switched to the high dose (again). As
a consequence, a total of 73 patients received low-dose
treatment, and 72 patients received high-dose treatment at
some time during the study. Ten patients on low dose (of
which, 8 completed the study) and 9 patients on high dose (of
which, 1 completed the study) never had any change in dose
during the study.
A total of 66 patients (80%) completed the study, and 16
patients (20%) discontinued because of lack of eﬃcacy (re-
lapse according to the investigator; n = 8), physician decision
(n = 2), AEs (n = 3), or withdrawal by patient (n = 3).
Relapse rates of patients treated with high
dose (0.4 g/kg weekly)
Overall, relapse on high dose occurred in 7 of 72 patients
(10%) (tables 3 and 4). Six of these relapses occurred in
patients who were started on high dose and 1 in a patient who
was switched from low dose to high dose. Three of the 7
relapses occurring on the high dose were self-limiting,
meaning that they improved spontaneously without further
intervention.
Extension study patients who previously relapsed in PATH
had a relapse rate on high dose of 8% (2 of 24), and those who
did not relapse in PATH had a relapse rate of 10% (5 of 48).
Similarly, relapse rates on high dose in the extension study
were 8% (2 of 24) and 9% (2 of 23) for patients treated with
high or low dose in PATH irrespective if they were relapsers
or nonrelapsers. Only 1 of the 15 patients on high dose in the
extension study (7%) had a relapse who previously relapsed on
placebo in PATH. The lowest relapse rate (1 of 21, 5%) was
observed in patients who started high-dose treatment in PATH
and continued high-dose treatment in the extension study.
Of the 62 patients who started on the high dose, 52 were
switched to the low dose at W24, as was foreseen by the
original protocol (including 1 patient started on high dose
erroneously, when amendment was active and 1 patient
switching incorrectly after experiencing relapses on high
dose). Of those who relapsed under low dose (see below),
92% (24 of 26) recovered after reinitiating high dose. Thirty-
three patients completed the study on high-dose treatment.
Relapse rates of patients treatedwith low dose
(0.2 g/kg weekly)
Overall, relapses occurred in 35 of 73 patients (48%) treated
with low dose (tables 3 and 4). Nine relapses occurred in 20
patients (45%) who started treatment on the low dose, and 26
relapses occurred in 52 patients (50%) who had a planned
dose decrease from high to low dose.
Extension study patients who previously relapsed in PATH
had a relapse rate on low dose of 67% (16 of 24), and those
who did not relapse in PATH had a relapse rate of 39% (19 of
49). Similarly, relapse rates on low dose in the extension were
46% (11 of 24) and 38% (9 of 24) for patients treated with
Table 1 Baseline characteristics (N = 82)
Age, y; mean (SD) 57.6 (13.22)
Sex, n (%)
Male 50 (61.0)
Female 32 (39.0)
Weight, kg; mean (SD) 80.2 (18.89)
BMI, kg/m2; mean (SD) (n = 81) 26.7 (4.52)
Baseline INCAT score;
mean (SD) (n = 80)
2.6 (1.86)
Baseline MRC score; median
(min, max) (n = 78)
76 (47, 80)
Baseline I-RODS score; median
(min, max) (n = 71)
65 (19, 100)
Baseline mean grip strength
(dominant hand; kPa);
median (min, max) (n = 79)
67 (8, 157)
Abbreviations: BMI = body mass index; INCAT = Inflammatory Neuropathy
Cause and Treatment scale; I-RODS = InflammatoryNeuropathy-Rasch-Built
Overall Disability Scale; MRC = Medical Research Council.
Table 2 Subject disposition by treatment and relapse
status in the PATH study
PATH study treatment
and relapse status
Subjects (%)
Extension study
Initial IgPro20 dose
0.2 g/kg 0.4 g/kg Overall
N = 20 N = 62 N = 82
0.4 g/kg, n = 58
Nonrelapse 5 (25.0) 18 (29.0) 23 (28.0)
Relapse, n = 11 1 (5.0) 3 (4.8) 4 (4.9)
0.2 g/kg, n = 57
Nonrelapse 6 (30.0) 15 (24.2) 21 (25.6)
Relapse, n = 19 3 (15.0) 4 (6.5) 7 (8.5)
Placebo, n = 57
Nonrelapse 3 (15.0) 9 (14.5) 12 (14.6)
Relapse, n = 32 2 (10.0) 13 (21.0) 15 (18.3)
N = number of subjects in the extension study; n = number of subjects in the
PATH study.
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high or low dose in PATH irrespective if they were relapsers
or nonrelapsers. In addition, 67% (10 of 15) of patients re-
lapsed in this study who also had a relapse on placebo in
PATH. However, patients who did not relapse on placebo in
the PATH study had a 50% chance to relapse on low dose (5
of 10) and 20% on high dose (2 of 10).
Of the 62 patients who started on high dose, 52 were switched
to low dose after 24 weeks of whom 26 relapsed (50%). From
the 28 patients who were switched from high to low dose and
completed the PATH study without relapse on both IgPro20
doses, 9 (32%) experienced a relapse. Thirty-three patients
completed the study on low-dose treatment.
MRC, I-RODS, and grip strength
Patients presented with similar baseline median scores for
MRC, I-RODS, and grip strength (table e-2, links.lww.com/
NXI/A124). At relapse, all clinical scores showed signiﬁcant
deterioration. MRC sum scores deteriorated by 3 points in
low-dose patients and 8 points in high-dose patients. I-RODS
scores deteriorated by 8 and 13 centile points and grip
strength deteriorated by 6 and 12 kPa.
Safety
Most patients were treated with both high- and low-dose
SCIG. Seventy-three patients received the low dose (0.2
g/kg), and 72 patients received the high dose (0.4 g/kg)
weekly during the study. Sixty-two patients (76%) had 180
AEs (table 5 and table e-3, links.lww.com/NXI/A124). More
patients had AEs during high-dose treatment than during low-
dose treatment. However, the rate of AEs per infusion in the
high-dose group was one half that of the low-dose group.
There was an overall low frequency of systemic side eﬀects;
headaches were not reported by any patient during low-dose
treatment and in 4 patients (5.6%) under the 0.4 g/kg dose.
Figure Study profile
*Including one subject who relapsed twice on HD but switched
to LD at W24 and discontinued due to lack of efficacy.
Table 3 Relapse rates and time to first relapse by treatment and status at end of the PATH study
Extension study treatment
0.2 g/kg 0.4 g/kg Overall
Relapse ratesa in the extension study
Subjects treated in the extension study 73 72 82
Relapsers in the extension study, subjects (%) 35 (47.9) 7 (9.7) 41 (50.0)
Nonrelapsers in the extension study, subjects (%) 38 (52.1) 65 (90.3) 41 (50.0)
a These relapse rates refer to all subjects in the extension study, irrespective of treatment and status at the end of the PATH study. Status at the end of the
PATH study (nonrelapser/relapser) was as defined by the primary end point.
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Nausea occurred in 2 patients (2.8%). No case of hypertension
was reported. A total of 18 patients (22%) had 40 local reactions.
Themajority of AEs were eithermild (62%) ormoderate (29%).
Twelve severe AEs were reported in 8 patients (10%). None of
the severe AEs were causally related, except 3 local reactions
experienced by 1 patient. All severe AEs resolved, except for
a preexisting vitamin D deﬁciency in 1 patient in the low-dose
group, and 1 AE of infusion site swelling and 1AE of infusion site
erythema, occurring in the same patient in the high-dose group.
Seven patients (9%) had 8 serious AEs (SAEs); none of these
events were causally related to IgPro20. All patients recovered
from these SAEs. Two patients discontinued the study because
of AEs while on low dose and 1 patient while on high dose.
IgG serum levels
Serum trough IgG levels were similar at baseline for low- and
high-dose-treated patients (median 21.1 and 21.2 g/L). After
24 weeks of treatment, trough levels declined in low-dose
patients but were stable in high-dose patients (median change
−1.0 and −0.4 g/L, respectively.). This was more pronounced
when patients had a relapse where trough levels had decreased by
−5.3 g/L in low-dose patients and −0.2 g/L in high-dose patients.
Patient preference
At study exit, overall 82.4% of patients preferred their current SC
treatment (table 4). Themost frequent reason was that treatment
was believed to oﬀer more independence (71.6%), followed by
“spend less time with current therapy” (40.5%), “preferred fre-
quency of administration” (37.8%), and “seem to feel fewer side
eﬀects” (31.1%). In comparison, overall 12.2% of patients pre-
ferred IV treatment, and 5.4% had no preference (table 4).
Discussion
This study was designed to investigate the long-term safety
and eﬃcacy of IgPro20 in the maintenance treatment of
CIDP. Overall, the safety ﬁndings in the extension study were
consistent with those from the PATH study and the already
known safety proﬁle for IgPro20. There was a low frequency
of systemic side eﬀects such as headache, nausea, or hyper-
tension. In IVIG marketing approval studies, headaches are
frequently reported in approximately 30% of patients, hy-
pertension in 9%–14%, and nausea in 6%–11%.15,19 One in 5
patients had a local reaction (e.g., infusion site swelling or
erythema) with a lower rate in the 0.2 g/kg dosed patients.
No new safety ﬁndings were identiﬁed. Most AEs were mild
or moderate, and no SAEs were assessed as related to therapy.
Patients who were treated with the 0.4 g/kg dose showed
a low relapse rate (overall approximately 10%) compared with
patients treated with the 0.2 g/kg dose (44%). When con-
sidering the treatment assignment in the preceding PATH
study, it appeared that those patients who were treated with
the high dose (in PATH) and continued high-dose treatment
in the extension study had a very low relapse rate in the
extension study (5%). In addition, some patients relapsing on
the high dose recovered without further intervention, in-
dicating that these relapses were most likely disease ﬂuctua-
tions. On the other hand, patients on low dose showed
consistently higher relapse rates, regardless whether initially
started on this dose or after dose switch from high- to low-
dose SCIG. Consistent with clinical relapse were the ﬁndings
of IgG level decreases in the low-dose group, particularly in
those who relapsed.
An important ﬁnding in this study was that patients who
relapsed on low dose could successfully be switched back to
high dose with 92% (24 of 26) of patients fully recovering
back to previous clinical levels. This has practical implications,
as physicians might want to reduce a patient’s dose after
a period of clinical stability. Reinitiating the high dose can be
Table 4 Subject preference for treatment responses (last postdose observation)
0.2 IgPro20
(N = 73)
0.4 IgPro20
(N = 72)
Overall
(N = 82)
Prefer current SC treatment 35 (89.7) 50 (83.3) 61 (82.4)
Prefer the frequency of administration of my current therapy 13 (33.3) 22 (36.7) 28 (37.8)
Believe that my current therapy offers me more independence for doing the things I want to do 29 (74.4) 44 (73.3) 53 (71.6)
Seem to feel fewer side effects from my current therapy 14 (35.9) 19 (31.7) 23 (31.1)
Believe that overall I will spend less time dealing with my current therapy 16 (41.0) 24 (40.0) 30 (40.5)
My current therapy works better 11 (28.2) 21 (35.0) 26 (35.1)
Prefer my current therapy for another reason 3 (7.7) 5 (8.3) 6 (8.1)
Prefer previous IV treatment 2 (5.1) 7 (11.7) 9 (12.2)
No preference 2 (5.1) 3 (5.0) 4 (5.4)
Last postdose observation is the observation at the last visit (including unscheduled visits) for which an observation is available in the corresponding dose
group.
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seen as an eﬀective “rescue strategy” for relapsed patients on
lower doses.
Despite these diﬀerences in relapse rates, the study also
showed that approximately 68% of patients who completed
PATH without a relapse remained stable after switching from
high to low dose in the extension study. We conclude from
this observation that for a considerable number of patients,
the low dose was an appropriate treatment, albeit that more
than two-thirds of these patients were treated with high dose
for at least 24 weeks ﬁrst.
When exiting the study, more than 80% of patients preferred
their SC treatment over IV treatment, which they had
Table 5 All AEs reported in ≥2% of subjects
System Organ Class Preferred
Term
0.2 g/kg IgPro20 0.4 g/kg IgPro20 Overall
No. (%) of
subjects
with
an event
No. of events
(rate/infusion)c
No. (%) of
subjects
with
an event
No. of events
(rate/infusion)c
No. (%) of subjects
with an event
No. of events
(rate/infusion)c
N = 73 n = 1,408 N = 72 N = 4,145 N = 82 n = 5,553
Any AE (treatment emergent) 33 (45.2) 77 (0.055) 46 (63.9) 103 (0.025) 62 (75.6) 180 (0.032)
General disorders and
administration site
conditionsa
8 (11.0) 25 (0.018) 18 (25.0) 23 (0.006) 22 (26.8) 48 (0.009)
Fatigue 1 (1.4) 1 (< 0.001) 3 (4.2) 3 (< 0.001) 4 (4.9) 4 (< 0.001)
Local reactionsb 7 (9.6) 24 (0.017) 13 (18.1) 16 (0.004) 18 (22.0) 40 (0.007)
Infusion site erythema 4 (5.5) 5 (0.004) 4 (5.6) 4 (< 0.001) 7 (8.5) 9 (0.002)
Infusion site swelling 3 (4.1) 5 (0.004) 6 (8.3) 6 (0.001) 9 (11.0) 11 (0.002)
Infusion site pain 1 (1.4) 8 (0.006) 2 (2.8) 2 (< 0.001) 3 (3.7) 10 (0.002)
Infusion site mass 0 0 2 (2.8) 2 (< 0.001) 2 (2.4) 2 (< 0.001)
Infections and infestations 8 (11.0) 10 (0.007) 15 (20.8) 16 (0.004) 20 (24.4) 26 (0.005)
Nasopharyngitis 6 (8.2) 7 (0.005) 6 (8.3) 6 (0.001) 11 (13.4) 13 (0.002)
Urinary tract infection 0 0 2 (2.8) 2 (< 0.001) 2 (2.4) 2 (< 0.001)
Musculoskeletal and
connective tissue disorders
4 (5.5) 5 (0.004) 10 (13.9) 12 (0.003) 12 (14.6) 17 (0.003)
Back pain 0 0 3 (4.2) 3 (< 0.001) 3 (3.7) 3 (< 0.001)
Muscle spasms 1 (1.4) 1 (< 0.001) 2 (2.8) 2 (< 0.001) 3 (3.7) 3 (< 0.001)
Nervous system disorder 3 (4.1) 3 (0.002) 8 (11.1) 15 (0.004) 10 (12.2) 18 (0.003)
Headache 0 0 4 (5.6) 5 (0.001) 4 (4.9) 5 (< 0.001)
Dizziness 1 (1.4) 1 (< 0.001) 2 (2.8) 4 (< 0.001) 2 (2.4) 5 (< 0.001)
Sciatica 1 (1.4) 1 (< 0.001) 2 (2.8) 2 (< 0.001) 3 (3.7) 3 (< 0.001)
Gastrointestinal disorders 3 (4.1) 4 (0.003) 4 (5.6) 8 (0.002) 6 (7.3) 12 (0.002)
Nausea 0 0 2 (2.8) 2 (< 0.001) 2 (2.4) 2 (< 0.001)
Vomiting 1 (1.4) 1 (< 0.001) 2 (2.8) 2 (< 0.001) 2 (2.4) 3 (< 0.001)
Diarrhea 2 (2.7) 2 (0.001) 0 0 2 (2.4) 2 (< 0.001)
Injury, poisoning, and
procedural complications
4 (5.5) 5 (0.004) 5 (6.9) 6 (0.001) 8 (9.8) 11 (0.002)
Fall 2 (2.7) 2 (0.001) 1 (1.4) 1 (< 0.001) 3 (3.7) 3 (< 0.001)
Abbreviations: AE = adverse event (treatment emergent); N = total number of subjects; n = total number of infusions; SOC = System Organ Class.
a Preferred terms in the virtual SOC of local reactions were not repeated in the SOC of general disorders and administration site conditions.
b The virtual System Organ Class of Local Reactions included all AEs reported within the MedDRA high-level terms “Administration Site Reactions NEC,”
“Infusion Site Reactions,” and “Injection Site Reactions.”
c The rate per infusion is calculated as the number of events divided by the overall number of infusions in the respective groups.
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received before entry into the PATH and/or extension study.
The most common named advantages were gain of in-
dependence, less time spent for SC therapy, preferred fre-
quency of administration, and less felt side eﬀects. However,
important to realize is that this may be a selected group of
patients preferring SCIG (as they volunteered for the PATH
trial and then again for the extension study).
The PATH study was enriched with IVIG responders, as the
main goal was to investigate maintenance treatment. Leaving
out patients who had successfully been rescued from a relapse
in the PATH study would have biased this study even more
toward treatment responders.
Only a few studies with long-term SCIG treatment in CIDP
have been published. Markvardsen et al. followed up on 17
patients from their placebo-controlled study for 12 months, of
which 16 completed the study.20,21 Four patients experienced
a decline in muscle strength, 10 experienced an increase, and 2
remained unchanged. None of the patients experienced an
increase in disability. The SCIG dosage used was 0.33–0.37 g/
kg/wk, which is close to the 0.4 g/kg/wk used in our study.
Cocito et al.22 reported a 2-year study of 6 Italian neurological
centers, which included 45 patients with CIDP. The SCIG
dose administered was equivalent to a 1:1 conversion from
the previous IVIG dose (usually corresponding to a 0.33 g/kg
weekly SCIG dose). In only about 13% of patients were dose
adjustments required.
In summary, eﬃcacy ﬁndings conﬁrmed that high-dose
IgPro20, 0.4 g/kg weekly, oﬀered a higher likelihood for
maintaining patients’ health status than low dose, 0.2 g/kg
weekly. Yet, a substantial proportion of patients could be
down-titrated to low dose without further worsening. This
emphasizes that in clinical practice, dose reductions are rec-
ommended, tailored to the individual needs of patients, and
that by increasing the dose, patients who relapse can be
rescued.
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